AnaptysBio, Inc.
ANAB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $852,246 | $639,582 | $569,672 | $375,778 |
| - Cash | $109,833 | $44,298 | $98,637 | $123,080 |
| + Debt | $14,606 | $346,457 | $15,575 | $16,037 |
| Enterprise Value | $757,019 | $941,741 | $486,610 | $268,735 |
| Revenue | $76,320 | $22,263 | $27,771 | $43,113 |
| % Growth | 242.8% | -19.8% | -35.6% | – |
| Gross Profit | $44,913 | -$15,561 | -$13,409 | $524 |
| % Margin | 58.8% | -69.9% | -48.3% | 1.2% |
| EBITDA | $38,238 | -$18,384 | -$20,618 | -$3,806 |
| % Margin | 50.1% | -82.6% | -74.2% | -8.8% |
| Net Income | $15,113 | -$38,630 | -$39,329 | -$21,784 |
| % Margin | 19.8% | -173.5% | -141.6% | -50.5% |
| EPS Diluted | 0.52 | -1.34 | -1.28 | -0.77 |
| % Growth | 138.8% | -4.7% | -66.2% | – |
| Operating Cash Flow | -$27,356 | -$40,244 | -$10,700 | -$66,672 |
| Capital Expenditures | -$12 | -$39 | -$35 | -$263 |
| Free Cash Flow | -$27,368 | -$40,283 | -$10,735 | -$66,935 |